A de novo ADCY5 mutation causes early-onset autosomal dominant chorea and dystonia

ABSTRACT Importance Apart from Huntington's disease, little is known of the genetics of autosomal dominant chorea associated with dystonia. Here we identify adenylate cyclase 5 (ADCY5) as a likely new causal gene for early‐onset chorea and dystonia. Observations Whole exome sequencing in a thre...

Full description

Saved in:
Bibliographic Details
Published inMovement disorders Vol. 30; no. 3; pp. 423 - 427
Main Authors Carapito, Raphael, Paul, Nicodème, Untrau, Meiggie, Le Gentil, Marion, Ott, Louise, Alsaleh, Ghada, Jochem, Pierre, Radosavljevic, Mirjana, Le Caignec, Cédric, David, Albert, Damier, Philippe, Isidor, Bertrand, Bahram, Seiamak
Format Journal Article
LanguageEnglish
Published United States Blackwell Publishing Ltd 01.03.2015
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:ABSTRACT Importance Apart from Huntington's disease, little is known of the genetics of autosomal dominant chorea associated with dystonia. Here we identify adenylate cyclase 5 (ADCY5) as a likely new causal gene for early‐onset chorea and dystonia. Observations Whole exome sequencing in a three‐generation family affected with autosomal dominant chorea associated with dystonia identified a single de novo mutation—c.2088+1G>A in a 5' donor splice‐site of ADCY5—segregating with the disease. This mutation seeming leads to RNA instability and therefore ADCY5 haploinsufficiency. Conclusions and Relevance Our finding confirms the genetic/clinical heterogeneity of the disorder; corroborated by previous identification of ADCY5 mutations in one family with dyskinesia‐facial myokymia and in two unrelated sporadic cases of paxoysmal choreic/dystonia‐facial myokymia; ADCY5's high expression in the striatum and movement disorders in ADCY5‐deficient mice. Hence ADCY5 genetic analyses may be relevant in the diagnostic workup of unexplained early‐onset hyperkinetic movement disorders. © 2014 International Parkinson and Movement Disorder Society
Bibliography:istex:7FE5845201E67E1A8EC8FD6BA96D81237D9519D8
ArticleID:MDS26115
ark:/67375/WNG-BV3FB6L1-5
This study was supported by funds from the Strasbourg High Throughput Next Generation Sequencing facility (GENOMAX) and INSERM UMR_S 1109.
Nothing to report.
These authors contributed equally to this work
Relevant conflicts of interest/financial disclosures
Author roles may be found in the online version of this article.
Funding agencies
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
ObjectType-Feature-3
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0885-3185
1531-8257
DOI:10.1002/mds.26115